|
Synonyms: Betaferon® | Betaseron® | Extavia® | IFNb1b
IFN-β1b (recombinant human) is an approved drug (FDA (1993), EMA (1995))
Compound class:
Peptide or derivative
Comment: Compared to the sequence of endogenous IFN-β, IFN-β1b has a Ser to Cys substitution at position 17, but does not retain the glycosylation site at Asn80. It also lacks the initiating Met. This recombinant peptide is produced in E.coli.
|
| References |
|
1. Freedman MS. (2014)
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. Ther Adv Neurol Disord, 7 (6): 279-88. [PMID:25371710] |
|
2. Marziniak M, Meuth S. (2014)
Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis. Adv Ther, 31 (9): 915-31. [PMID:25182864] |
